Circulating Let-7 Family Members as Non-Invasive Biomarkers for Predicting Hepatocellular Carcinoma Risk after Antiviral Treatment among Chronic Hepatitis C Patients
HCC, a leading cause of cancer-related mortality, is diagnosed at advanced stages. Although antiviral therapy has reduced the risk of HCC among chronic hepatitis C (CHC) patients, the risk of HCC remains, thus, highlighting the unmet need for continuous surveillance. Therefore, stable and cost-effec...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-04-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/14/8/2023 |
| _version_ | 1797436453302566912 |
|---|---|
| author | Yi-Shan Tsai Ching-I Huang Pei-Chien Tsai Ming-Lun Yeh Chung-Feng Huang Meng-Hsuan Hsieh Ta-Wei Liu Yi-Hung Lin Po-Cheng Liang Zu-Yau Lin Shinn-Cherng Chen Jee-Fu Huang Wan-Long Chuang Chia-Yen Dai Ming-Lung Yu |
| author_facet | Yi-Shan Tsai Ching-I Huang Pei-Chien Tsai Ming-Lun Yeh Chung-Feng Huang Meng-Hsuan Hsieh Ta-Wei Liu Yi-Hung Lin Po-Cheng Liang Zu-Yau Lin Shinn-Cherng Chen Jee-Fu Huang Wan-Long Chuang Chia-Yen Dai Ming-Lung Yu |
| author_sort | Yi-Shan Tsai |
| collection | DOAJ |
| description | HCC, a leading cause of cancer-related mortality, is diagnosed at advanced stages. Although antiviral therapy has reduced the risk of HCC among chronic hepatitis C (CHC) patients, the risk of HCC remains, thus, highlighting the unmet need for continuous surveillance. Therefore, stable and cost-effective biomarkers, such as circulating microRNAs, must be identified. We aimed to clarify whether serum levels of the Let-7 family can predict HCC risk in patients with CHC using univariate and multivariate Cox’s proportional hazards model. We analyzed the sera of 54 patients with CHC who developed HCC after antiviral therapy and compared the data with those of 173 patients without HCC development. The Let-7 family (except for let-7c) exhibited significant negative correlations with the fibrosis score (<i>r</i> = −0.2736 to −0.34, <i>p</i> = 0.0002 to <0.0001). After Cox’s regression model was used to adjust for age, sex, HCV genotype, and FIB-4 ≥ 3.25, patients with CHC with let-7i median ≥ −1.696 (adjusted hazard ratio [aHR] = 0.31, 95% CI: 0.08–0.94, <i>p</i> = 0.0372) in the sustained virologic response (SVR) groups and ≥−1.696 (aHR = 0.09, 95% CI: 0.08–0.94, <i>p</i> = 0.0022) in the non-SVR group were less likely to develop HCC. Thus, circulating let-7i can be used for early CHC surveillance in patients with HCC risk after antiviral treatment. |
| first_indexed | 2024-03-09T11:02:46Z |
| format | Article |
| id | doaj.art-13aff33c4f94448d8d8aa4184908956d |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-09T11:02:46Z |
| publishDate | 2022-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-13aff33c4f94448d8d8aa4184908956d2023-12-01T01:08:57ZengMDPI AGCancers2072-66942022-04-01148202310.3390/cancers14082023Circulating Let-7 Family Members as Non-Invasive Biomarkers for Predicting Hepatocellular Carcinoma Risk after Antiviral Treatment among Chronic Hepatitis C PatientsYi-Shan Tsai0Ching-I Huang1Pei-Chien Tsai2Ming-Lun Yeh3Chung-Feng Huang4Meng-Hsuan Hsieh5Ta-Wei Liu6Yi-Hung Lin7Po-Cheng Liang8Zu-Yau Lin9Shinn-Cherng Chen10Jee-Fu Huang11Wan-Long Chuang12Chia-Yen Dai13Ming-Lung Yu14Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 80708, TaiwanHepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 80708, TaiwanHepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 80708, TaiwanHepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 80708, TaiwanHepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 80708, TaiwanHepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 80708, TaiwanHepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 80708, TaiwanHepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 80708, TaiwanHepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 80708, TaiwanHepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 80708, TaiwanHepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 80708, TaiwanHepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 80708, TaiwanHepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 80708, TaiwanHepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 80708, TaiwanHepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 80708, TaiwanHCC, a leading cause of cancer-related mortality, is diagnosed at advanced stages. Although antiviral therapy has reduced the risk of HCC among chronic hepatitis C (CHC) patients, the risk of HCC remains, thus, highlighting the unmet need for continuous surveillance. Therefore, stable and cost-effective biomarkers, such as circulating microRNAs, must be identified. We aimed to clarify whether serum levels of the Let-7 family can predict HCC risk in patients with CHC using univariate and multivariate Cox’s proportional hazards model. We analyzed the sera of 54 patients with CHC who developed HCC after antiviral therapy and compared the data with those of 173 patients without HCC development. The Let-7 family (except for let-7c) exhibited significant negative correlations with the fibrosis score (<i>r</i> = −0.2736 to −0.34, <i>p</i> = 0.0002 to <0.0001). After Cox’s regression model was used to adjust for age, sex, HCV genotype, and FIB-4 ≥ 3.25, patients with CHC with let-7i median ≥ −1.696 (adjusted hazard ratio [aHR] = 0.31, 95% CI: 0.08–0.94, <i>p</i> = 0.0372) in the sustained virologic response (SVR) groups and ≥−1.696 (aHR = 0.09, 95% CI: 0.08–0.94, <i>p</i> = 0.0022) in the non-SVR group were less likely to develop HCC. Thus, circulating let-7i can be used for early CHC surveillance in patients with HCC risk after antiviral treatment.https://www.mdpi.com/2072-6694/14/8/2023chronic hepatitis CLet-7 familyhepatitis C virusmiRNAbiomarkerhepatocellular carcinoma |
| spellingShingle | Yi-Shan Tsai Ching-I Huang Pei-Chien Tsai Ming-Lun Yeh Chung-Feng Huang Meng-Hsuan Hsieh Ta-Wei Liu Yi-Hung Lin Po-Cheng Liang Zu-Yau Lin Shinn-Cherng Chen Jee-Fu Huang Wan-Long Chuang Chia-Yen Dai Ming-Lung Yu Circulating Let-7 Family Members as Non-Invasive Biomarkers for Predicting Hepatocellular Carcinoma Risk after Antiviral Treatment among Chronic Hepatitis C Patients Cancers chronic hepatitis C Let-7 family hepatitis C virus miRNA biomarker hepatocellular carcinoma |
| title | Circulating Let-7 Family Members as Non-Invasive Biomarkers for Predicting Hepatocellular Carcinoma Risk after Antiviral Treatment among Chronic Hepatitis C Patients |
| title_full | Circulating Let-7 Family Members as Non-Invasive Biomarkers for Predicting Hepatocellular Carcinoma Risk after Antiviral Treatment among Chronic Hepatitis C Patients |
| title_fullStr | Circulating Let-7 Family Members as Non-Invasive Biomarkers for Predicting Hepatocellular Carcinoma Risk after Antiviral Treatment among Chronic Hepatitis C Patients |
| title_full_unstemmed | Circulating Let-7 Family Members as Non-Invasive Biomarkers for Predicting Hepatocellular Carcinoma Risk after Antiviral Treatment among Chronic Hepatitis C Patients |
| title_short | Circulating Let-7 Family Members as Non-Invasive Biomarkers for Predicting Hepatocellular Carcinoma Risk after Antiviral Treatment among Chronic Hepatitis C Patients |
| title_sort | circulating let 7 family members as non invasive biomarkers for predicting hepatocellular carcinoma risk after antiviral treatment among chronic hepatitis c patients |
| topic | chronic hepatitis C Let-7 family hepatitis C virus miRNA biomarker hepatocellular carcinoma |
| url | https://www.mdpi.com/2072-6694/14/8/2023 |
| work_keys_str_mv | AT yishantsai circulatinglet7familymembersasnoninvasivebiomarkersforpredictinghepatocellularcarcinomariskafterantiviraltreatmentamongchronichepatitiscpatients AT chingihuang circulatinglet7familymembersasnoninvasivebiomarkersforpredictinghepatocellularcarcinomariskafterantiviraltreatmentamongchronichepatitiscpatients AT peichientsai circulatinglet7familymembersasnoninvasivebiomarkersforpredictinghepatocellularcarcinomariskafterantiviraltreatmentamongchronichepatitiscpatients AT minglunyeh circulatinglet7familymembersasnoninvasivebiomarkersforpredictinghepatocellularcarcinomariskafterantiviraltreatmentamongchronichepatitiscpatients AT chungfenghuang circulatinglet7familymembersasnoninvasivebiomarkersforpredictinghepatocellularcarcinomariskafterantiviraltreatmentamongchronichepatitiscpatients AT menghsuanhsieh circulatinglet7familymembersasnoninvasivebiomarkersforpredictinghepatocellularcarcinomariskafterantiviraltreatmentamongchronichepatitiscpatients AT taweiliu circulatinglet7familymembersasnoninvasivebiomarkersforpredictinghepatocellularcarcinomariskafterantiviraltreatmentamongchronichepatitiscpatients AT yihunglin circulatinglet7familymembersasnoninvasivebiomarkersforpredictinghepatocellularcarcinomariskafterantiviraltreatmentamongchronichepatitiscpatients AT pochengliang circulatinglet7familymembersasnoninvasivebiomarkersforpredictinghepatocellularcarcinomariskafterantiviraltreatmentamongchronichepatitiscpatients AT zuyaulin circulatinglet7familymembersasnoninvasivebiomarkersforpredictinghepatocellularcarcinomariskafterantiviraltreatmentamongchronichepatitiscpatients AT shinncherngchen circulatinglet7familymembersasnoninvasivebiomarkersforpredictinghepatocellularcarcinomariskafterantiviraltreatmentamongchronichepatitiscpatients AT jeefuhuang circulatinglet7familymembersasnoninvasivebiomarkersforpredictinghepatocellularcarcinomariskafterantiviraltreatmentamongchronichepatitiscpatients AT wanlongchuang circulatinglet7familymembersasnoninvasivebiomarkersforpredictinghepatocellularcarcinomariskafterantiviraltreatmentamongchronichepatitiscpatients AT chiayendai circulatinglet7familymembersasnoninvasivebiomarkersforpredictinghepatocellularcarcinomariskafterantiviraltreatmentamongchronichepatitiscpatients AT minglungyu circulatinglet7familymembersasnoninvasivebiomarkersforpredictinghepatocellularcarcinomariskafterantiviraltreatmentamongchronichepatitiscpatients |